Wang, Jingjun
Ritchey, Mary E.
Reynolds, Kamika
Carbonneau, Madeleine
Carrera, Adam
Goti, Noelia
Horn, John R.
Girman, Cynthia J.
Funding for this research was provided by:
Urovant Sciences
Article History
Accepted: 16 April 2023
First Online: 23 May 2023
Declarations
:
: MER, JW, AC, and CJG developed the protocol. JW and MC analyzed the data. All authors contributed to the interpretation of data, revised the manuscript for intellectual content, and read and approved the final version.
: Funding for this analysis and for medical writing and editorial assistance was provided by Urovant Sciences (Irvine, CA).
: JW is an employee of Sumitovant Biopharma, Inc. MER was a consultant for CERobs Consulting, LLC, a consulting firm that was contracted by Urovant Sciences and consults with other pharmaceutical companies, at the time the work was conducted. KR was an employee of CERobs Consulting, LLC, at the time the work was conducted. MC was an employee of Roivant Sciences, Inc., and a consultant to Sumitovant Biopharma, Inc., at the time the work was conducted. AC is an employee of Urovant Sciences and Duke Health. NG is an employee of Urovant Sciences. JRH is a coauthor and publisher of <i>The Top 100 Drug Interactions: A Guide to Patient Management</i> and a consultant to Urovant Sciences and Seegnal US. CJG is the President of CERobs Consulting, LLC, a consulting firm that consults with pharmaceutical companies and was contracted by Urovant Sciences.
: Datasets generated and/or analyzed during the current study are available from Sumitovant Biopharma, Inc (Jingjun Wang; monica.wang@sumitovant.com), through licensing with IQVIA, Inc, and requests will be considered from qualified researchers on a case-by-case basis with the condition of IQVIA approval.
: This retrospective database analysis used deidentified claims data from the IQVIA PharMetrics<sup>®</sup> Plus database, which is compliant with the Health Insurance Portability and Accountability Act to protect patient privacy.
: Not applicable.
: Not applicable.